2022-05-06T11:30:26-05:00 2021-06-30 135565207 KPMG LLP 300 NORTH GREENE STREET SUITE 400 GREENSBORO NC 27401 990 2020-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen VP and Chief Financial Officer 2022-05-06 true Tim Hassen 999009999 SHAWN HUTCHINSON P01048557 3362753394 2022-05-06 2020 2022-09-23 18:48:47Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 225525285 false X www.omrf.org X 1946 OK Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease. 63 63 576 63 11725 9552 60164768 91435276 25257648 24073794 4241526 4418313 5464755 6089431 95128697 126016814 0 0 39778322 40750886 0 1847784 48830203 51587701 88608525 92338587 6520172 33678227 416096679 499810540 51737436 37672357 364359243 462138183 X OMRF is dedicated to developing a better understanding of more effective treatments for human disease. false false 35416463 0 24073794 Arthritis & Clinical Immunology/Clinical Operations - The National Institutes of Health named OMRF one of the lead sites for a nationwide Covid-19 vaccine clinical trial. The study assessed the antibody response to booster shots in people with autoimmune diseases who didn't mount strong immune responses to initial vaccination. "We're concerned about people with autoimmune conditions because they are more likely to have breakthrough episodes of Covid even when fully vaccinated," said Dr. Judith James, who led the trial at OMRF. The study examined whether giving volunteers a booster would elicit a stronger antibody response without flaring their underlying disease. The trial enrolled people with conditions that include multiple sclerosis, rheumatoid arthritis and lupus. 6855148 0 0 Cardiovascular Biology Research Program - With a major new mentoring grant from the NIH, OMRF will provide five years of funding for five junior scientists, who will each study various aspects of cellular metabolism. "Cellular metabolism is the sum of all chemical changes that take place in cells. When it is altered, it contributes to the origin of many common diseases," said Dr. Lijun Xia, principal investigator on the grant. He will serve as the lead scientific mentor for the researchers, who joined OMRF following post-doctoral fellowships at Yale University, the University of Utah, Seattle Children's Research Institute, the University of Washington, and the La Jolla Institute for Immunology. 6454825 0 0 Aging and Metabolism Research Program - Dr. Michael Beckstead received a grant from the National Institute on Aging to investigate a possible connection between Alzheimer's disease and dopamine, a chemical responsible for voluntary movement and the perception of reward in the brain. Beckstead studies what can happen when things go wrong with dopamine neurons, ranging from Parkinson's disease (too little) to drug addiction (too much). "Although dopamine has never been studied in context with Alzheimer's, we have a lot of evidence to suggest that it's involved, especially in the initial stages of disease," he said. 37516382 0 4691655 Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Genetic Models of Disease and other scientific and research support services. 37516382 4691655 86242818 true true false true false false false false true true true false true true true true true false false true false false false false false false false false true true false false false false false false false false true true true false false false true false false false false true 115 0 true 576 true true true false false false true true true true false false false true true false false false X 63 63 false false false false false false false true true false false true true true true true true true true false OK X X Tim Hassen VP and Chief Financial Officer 4052717421 825 NE 13th Street Oklahoma City OK 73104 Albers Leigh Ann Board Member 1.0 X 0 0 0 Anoatubby Bill Board Member 1.0 X 0 0 0 Bell Sharon Board Member 1.0 X 0 0 0 Benbrook Bruce Board Member 1.0 X 0 0 0 Benham Lance Board Member 1.0 X 0 0 0 Boghetich JII Board Member 1.0 X 0 0 0 Braught Barbara Board Member 1.0 X 0 0 0 Brown Randy Board Member 1.0 X 0 0 0 Burgess Ellen Board Member 1.0 X 0 0 0 Carolina Mike Board Member 1.0 X 0 0 0 Cason Len Board Member 1.0 X 0 0 0 Cawley Michael Board Member 1.0 X 0 0 0 Champlin Hiram Board Member 1.0 X 0 0 0 Collins Mark Board Member 1.0 X 0 0 0 Drake Ramsey Board Member 1.0 X 0 0 0 Duncan Walt Board Member 1.0 X 0 0 0 Eagan Claire Board Member 1.0 X 0 0 0 Edwards Carl Board Member 1.0 X 0 0 0 Everest Christy Board Member 1.0 X 0 0 0 Everest Tricia Board Member 1.0 X 0 0 0 Felton Ann Board Member 1.0 X 0 0 0 Fergeson Ken Board Member 1.0 X 0 0 0 Funke Mark Board Member 1.0 X 0 0 0 Gamble Gerald Board Member 1.0 X 0 0 0 Griffin John Board Member 1.0 X 0 0 0 Groendyke Virginia Board Member 1.0 X 0 0 0 Haglund Jacqui Board Member 1.0 X 0 0 0 Hall Brooks Board Member 1.0 X 0 0 0 Hargis Burns Board Member 1.0 X 0 0 0 Hatfield Judy Board Member 1.0 X 0 0 0 Hawley Bill Board Member 1.0 X 0 0 0 Henry Kim Board Member 1.0 X 0 0 0 Hogan Randy Board Member 1.0 X 0 0 0 Holmes Jerome Board Member 1.0 X 0 0 0 Hudson Cliff Board Member 1.0 X 0 0 0 Irani Ronnie Board Member 1.0 X 0 0 0 Jameson Brett Board Member 1.0 X 0 0 0 Johnstone Bill Board Member 1.0 X 0 0 0 Kelly Michael Board Member 1.0 X 0 0 0 Kern Terence Board Member 1.0 X 0 0 0 Kerr Lou Board Member 1.0 X 0 0 0 Levy Harrison Board Member 1.0 X 0 0 0 Little Dan Board Member 1.0 X 0 0 0 Loughridge Bill Board Member 1.0 X 0 0 0 Mahaney Mindy Board Member 1.0 X 0 0 0 McCarty Jack Board Member 1.0 X 0 0 0 Morris Jim Board Member 1.0 X 0 0 0 Nichols Larry Board Member 1.0 X 0 0 0 Parry Richard Board Member 1.0 X 0 0 0 Patten Rebecca Board Member 1.0 X 0 0 0 Payne Bond Board Member 1.0 X 0 0 0 Pollard Barry Board Member 1.0 X 0 0 0 Rainbolt David Board Member 1.0 X 0 0 0 Replogle Dee Board Member 1.0 X 0 0 0 Rooney Pat Board Member 1.0 X 0 0 0 Ross Bob Board Member 1.0 X 0 0 0 Samis Mike Board Member 1.0 X 0 0 0 Saxon John Board Member 1.0 X 0 0 0 Schulte Paul Board Member 1.0 X 0 0 0 Stough Phyllis Board Member 1.0 X 0 0 0 Swimmer Ross Board Member 1.0 X 0 0 0 Switzer Becky Board Member 1.0 X 0 0 0 Taylor Steven Board Member 1.0 X 0 0 0 Thorpe Betsy Board Member 1.0 X 0 0 0 Walton Greg Board Member 1.0 X 0 0 0 Williams G Rainey Jr Board Member 1.0 X 0 0 0 Yauk Sarah Board Member 1.0 X 0 0 0 Cohen Adam Sr VP and General Counsel 50.0 X 268722 0 54313 Courtney Greenwood VP of Human Resources 50.0 X 175885 0 33529 Day Lisa VP of Government Affairs 50.0 X 135177 0 22543 Hassen Tim VP and CFO 50.0 X 256097 0 62256 James Judith VP of Clinical Affairs and Program Chair 50.0 X 462516 0 101269 McEver Rodger MD VP of Research 50.0 X 331697 0 43220 Prescott Stephen MD President and CEO 50.0 X 998260 0 43905 Voss Penny VP of Development 50.0 X 221536 0 58905 Gaffney Patrick MD Program Chair, Genes and Human Disease 50.0 X 301571 0 60021 Pardo Gabriel MD Associate Member, Arthritis and Clinical Immunology 50.0 X 336797 0 49902 Xia Lijun MD Program Chair, Cardiovascular Biology 50.0 X 281867 0 76606 Chelsea Berkley MD Clinical Assistant Member, Arthritis and Clinical Immunology 50.0 X 268448 0 29607 Joan Merrill MD Member, Arthritis and Clinical Immunology 50.0 X 251237 0 28146 Lupu Florea PhD Member, Cardiovascular Biology 50.0 X 287525 0 38729 Nath Swapan PhD Member, Arthritis and Clinical Immunology 50.0 X 287157 0 50965 Rezaie Alireza PhD Member, Cardiovascular Biology 50.0 X 265648 0 42202 Morgan Chip Director of Specialist Projects, Admin Operations 50.0 X 103480 0 182 Nair Manu VP of Technology Ventures 50.0 X 93583 0 8203 5327203 0 804503 67 true true false Infusion Management LLC 11233 Shadow Creek Pwky Suite 303 Pearland TX 77584 Medical Billing Services 19937643 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 468415 Grant Thornton LLP 211 N Robinson Suite 1200 Oklahoma City OK 73102 Audit services 104500 Ellwood Associates 33 W Monroe St Suite 1000 Chicago IL 60603 Investment Management Services 100761 4 112705 33263646 58058925 582357 91435276 Clinic Revenue 621990 24073794 24073794 0 0 0 0 24073794 6814512 5421 6809091 61618 61618 3943466 3104474 838992 400281 400281 0 400281 400281 97050228 426 99251504 256967 -2201276 -256541 -2457817 6304 -2464121 Laboratory Income 621500 1587181 1587181 Cafe Income 722514 158503 158503 0 0 0 0 1745684 126016814 28765449 11725 5804364 3770123 3052257 496330 221536 27747953 25671140 1093230 983583 2265596 2064708 114261 86627 4874562 4377059 311550 185953 2092652 1907099 105539 80014 201900 147265 54635 128500 128500 55583 55583 1270876 1270876 0 0 574281 365777 80198 128306 1221456 997098 173478 50880 3985073 3196624 788440 9 128196 113928 11632 2636 48727 33561 14974 192 617145 604895 12250 7912192 7583445 328747 271682 198163 73519 Lab supplies 6443218 6443218 Trainee costs 1428058 1428058 Inhouse 1164296 1142118 16189 5989 Subcontracts 24224175 24224175 1912343 1421352 388932 102059 92338587 86242816 4247987 1847784 3640 3640 29057583 13461294 9295029 12076179 6175900 7010620 0 0 0 0 0 0 12243 11361 465916 596373 242834178 151667074 94795181 91167104 113247515 153961065 21446654 27928033 0 141597018 193594871 416096679 499810540 10516507 10463099 2192510 1350878 31965000 16885000 0 0 0 0 0 7063419 8973380 51737436 37672357 X 124900551 146514111 239458692 315624072 364359243 462138183 416096679 499810540 X 33678227 35534870 28565843 X false true X true true true X 58391949 58406493 60132921 60164768 91435276 328531407 0 0 0 0 0 0 0 0 0 0 0 0 58391949 58406493 60132921 60164768 91435276 328531407 51904544 276626863 6182195 8549189 13563861 3495987 8109982 39901214 0 5304 81073 5337 10725 102439 732460 334103 347212 295959 158503 1868237 370403297 126703408 0.7468 0.7239 X Schedule A, Part II, Line 10 Schedule A, Part II, Line 10 Other income includes cafeteria sales as well as fundraising income that was not included in contributions. Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 732460.0, COLUMN B - 334103.0, COLUMN C - 347212.0, COLUMN D - 295959.0, COLUMN E - 158503.0, COLUMN F - 1868237.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 342533 false false 342533 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 116281093 18987421 39164262 0 4800000 0 169632776 115938978 26722 4715393 0 4400000 0 116281093 97512842 16719850 5906286 0 4200000 0 115938978 91545136 75342 9892364 0 4000000 0 97512842 82018035 246125 13280976 0 4000000 0 91545136 0.3013 0.3386 0.3601 true false 4080847 4080847 185665747 112143795 73521952 53082060 39523279 13558781 5524 5524 91167104 Other securites 27928033 F 27928033 Funds held in trust by others 162854841 Wills and Bequests 23930787 Cash Surrender Value of Life Insurance 6123051 Debt Issue Costs 133087 Deposits 441751 Accrued Interest Receivable 63270 Assets Held for Sale 47970 Minerals 114 193594871 Postretirement Benefits and Deferred Comp 8872272 Split Interest Agreements 101108 8973380 X 190117527 35534870 28565843 64100713 126016814 0 0 126016814 92338587 0 0 92338587 0 0 92338587 Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is a public foundation exempt from federal income tax under section 501(c)(3) of the internal revenue code except for amounts relating to unrelated business income. There were no known material unrelated business income taxes incurred in 2021 and accordingly, no provision for income taxes has been made in these financial statements. Management has reviewed the Foundation's tax position and concluded that there are no uncertain tax positions that require accrual in the consolidated financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2018. The statute of limitations will remain open for both federal and state purposes for any returns not filed. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - 28461078 PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - 104765 Europe (Including Iceland and Greenland) 0 1 Conference Travel 1972 Europe (Including Iceland and Greenland) 0 15 Program Services Student Program 15466 North America (Canada & Mexico only) 0 2 Conference Travel -1147 South Asia 0 1 Program Services Intellectual Property/Research Collaboration 823 Central America and the Caribbean 0 0 Investments 3710727 0 19 0 0 0 19 3727841 0 3727841 true false false false true false Schedule F, Part I, Line 3 Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions, however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as to learn from other scientists across the world. X X true true X X X X X false true false false false false false true false Prescott Stephen MD President and CEO 845386 0 105000 0 47874 0 31196 0 12709 0 1042165 0 0 0 James Judith VP of Clinical Affairs and Program Chair 415104 0 0 0 47412 0 89563 0 11706 0 563785 0 0 0 McEver Rodger MD VP of Research 283043 0 0 0 48654 0 30511 0 12709 0 374917 0 0 0 Cohen Adam Sr VP and General Counsel 220490 0 0 0 48232 0 43052 0 11261 0 323035 0 0 0 Hassen Tim VP and CFO 228595 0 150 0 27352 0 42205 0 20051 0 318353 0 0 0 Voss Penny VP of Development 200184 0 0 0 21352 0 45899 0 13006 0 280441 0 0 0 Courtney Greenwood VP of Human Resources 170685 0 0 0 5200 0 21808 0 11721 0 209414 0 0 0 Day Lisa VP of Government Affairs 131754 0 0 0 3423 0 11557 0 10986 0 157720 0 0 0 Gaffney Patrick MD Program Chair, Genes and Human Disease 286459 0 0 0 15112 0 40630 0 19391 0 361592 0 0 0 Pardo Gabriel MD Associate Member, Arthritis and Clinical Immunology 333295 0 390 0 3112 0 30511 0 19391 0 386699 0 0 0 Xia Lijun MD Program Chair, Cardiovascular Biology 256183 0 240 0 25444 0 57215 0 19391 0 358473 0 0 0 Nath Swapan PhD Member, Arthritis and Clinical Immunology 245555 0 370 0 41232 0 30854 0 20111 0 338122 0 0 0 Rezaie Alireza PhD Member, Cardiovascular Biology 218633 0 0 0 47015 0 28773 0 13429 0 307850 0 0 0 Lupu Florea PhD Member, Cardiovascular Biology 252910 0 70 0 34545 0 31196 0 7533 0 326254 0 0 0 Joan Merrill MD Member, Arthritis and Clinical Immunology 229183 0 40 0 22014 0 26675 0 1471 0 279383 0 0 0 Chelsea Berkley MD Clinical Assistant Member, Arthritis and Clinical Immunology 247396 0 20340 0 712 0 23112 0 6495 0 298055 0 0 0 Morgan Chip Director of Specialist Projects, Admin Operations 102400 0 500 0 580 0 0 0 182 0 103662 0 0 0 Nair Manu VP of Technology Ventures 88312 0 75 0 5196 0 8203 0 0 0 101786 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel First class travel is allowed for the CEO to allow him to accomplish work related to tasks while traveling. Schedule J, Part I, Line 1a Travel for companions Travel for companions is allowed in certain limited circumstances where the companion's presence has a benefit to the Foundation but does not qualify as a business expense under IRS rules. In those limited cases the companion's travel expenses are treated as taxable compensation. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Board of the Foundation periodically uses non-qualified retirement plans as a retention tool. The amount reported is the amount vested in the 457(f) plan. The remaining amount of the plan is not vested and is subject to substantial risk of forfeiture. Schedule J, Part I, Line 7 Non-fixed payments The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. A Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 736194355 000000000 2016-07-13 29535000 Refunding of prior year 2008 bond false false false A 12650000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2016 false true true true A false false false true true 0.0171 0.0 0.0171 false false true A false false false true false false false false true A true Schedule K, Part I 07/13/2016 29535000 Oklahoma Industries Authority In July 2016, the Foundation entered into advanced refinancing of the Series 2008 bonds. The Foundation issued $43,955,000 of OIA Series 2008 Revenue Bonds (the "Series 2008 Bonds") dated July 1, 2008; the proceeds from this bond were used to construct and equip a new research facility. The Series 2008 Bonds were defeased when the Foundation issued $29,535,000 of OIA Series 2016 Revenue Bonds (the "Series 2016 Bonds") dated July 13, 2016. The Series 2016 bonds mature on July 1, 2026 and bear interest at the stated rate of 1.81% per annum. Payments of principal and interest began January 1, 2017 and are due January 1st and July 1st of each year. The Series 2016 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was $2,953,500 as of June 30, 2021. Schedule K, Part IV, Line 2c COLUMN A Issuer name: Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 The calculation for computing no rebate due was performed on 07/01/2021 Michelle Morgan Related officer 24550 Employment false X 17 582357 Market value 0 false true true Schedule M, Part I, Line 32b Third parties used to solicit, process, or sell noncash contributions The Foundation contracts with a service organization who solicits the donation of vehicles. The service organization is responsible for communication with the donor as well as the selling process. The Foundation receives a check for 80% of the proceeds from the sale of the vehicle. Form 990, Part III, Line 4d Description of other program services (Expenses $ 37,516,382 including grants of $ 0)(Revenue $ 4,691,655) Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Genetic Models of Disease and other scientific and research support services. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared by the Foundation, internally reviewed by the CFO. The Form 990-T is externally reviewed by the tax department of a public accounting firm. A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Line 15a Process to establish compensation of top management official Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 15b Process to establish compensation of other employees Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 18 How forms are made available to the public The Foundation's Form 990 for the last three years are publicly available on the Foundation's website, as well as on Guidestar and other nonprofit databases. Form 1023, 990, and 990-T are provided upon request. Form 990, Part VI, Line 19 Required documents available to the public The Foundation's governing documents, conflict of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - 28461078; PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - 104765; Form 990, Part VI Section A, Line 2 The Foundation currently has 63 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Culbertson Plaza LLC 825 NE 13th Street Oklahoma City OK 73104 842527142 Manage real property known as the Culbertson Plaza Shopping Center OK 86268 1450246 Oklahoma Medical Research Foundation